Inventor · disambiguated record
Ching-Hsuan Hsu
Also filed as: HSU CHING-HSUAN
6 granted patents·5 pending applications·3 citations·filing 2016–2025
72Inventor score
Top patents by PatentIndex Score
11 records- 0179US11780922B2Bifunctional proteins combining checkpoint blockade for targeted therapyAP BIOSCIENCES INC·Filed 2020·Granted Oct 10, 2023·1 cites·15 claims
- 0279US11299531B2Fusion protein comprising a ligand binding domain of VEGF and PDGFALLGENESIS BIOTHERAPEUTICS INC·Filed 2016·Granted Apr 12, 2022·2 cites·18 claims
- 0378US12312409B2Bispecific CD137-binding antibodies for T-cell activationAP BIOSCIENCES INC·Filed 2023·Granted May 27, 2025·0 cites·9 claims
- 0478US12304961B2PD-L1 and OX40 binding proteins for cancer regulationAP BIOSCIENCES INC·Filed 2023·Granted May 20, 2025·0 cites·19 claims
- 0572US2025346678A1OX40 Binding Proteins for Cancer RegulationAP BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 0672US2023322931A1Bifunctional Proteins Combining Checkpoint Blockade for Targeted TherapyAP BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 0771US2025270338A1Antibodies for t-cell activationAP BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 0866US11643470B2PD-L1 and OX40 binding proteins for cancer RegulationAP BIOSCIENCES INC·Filed 2020·Granted May 9, 2023·0 cites·27 claims
- 0966US2025154273A1PD-L1 and OX40 Binding Proteins for Cancer RegulationAP BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1064US11725058B2CD137 antibodies for T-cell activationAP BIOSCIENCES INC·Filed 2020·Granted Aug 15, 2023·0 cites·12 claims
- 1159US2025026841A1Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapyAP BIOSCIENCES INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ching-Hsuan Hsu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →